[1] Kasi PM, Tawbi HA, Oddis CV, et al.Clinical review:serious adverse events associated with the use of rituximab-a critical care perspective[J].Crit Care,2012,16(4):231. [2] 平宝红, 岳春燕, 朱阳敏, 等. 利妥昔单抗相关的间质性肺炎文献复习:附2例报告[J].南方医科大学学报,2015,35(1):129-132. [3] Naqibullah M, Shaker SB, Bach KS, et al. Rituximab-induced interstitial lung disease:five case reports[J]. Eur Clin Respir J, 2015, 2(1):27178. [4] Zhou X, Hu W, Qin X. The role of complement in the mechanism of action of rituximab for B-cell lymphoma:implications for therapy[J]. Oncologist,2008,13(9):954-966. [5] 吕慧娟, 董玲, 李维, 等. 利妥昔单抗相关间质性肺炎的临床分析[J].中国肿瘤临床,2016,43(7):291-297. [6] Liu X, Hong XN, Gu YJ, et al. Interstitial pneumonitis during rituximab-containing chemotherapy for non-Hodgkin lymphoma[J]. Leuk Lymphoma,2008,49(9):1778-1783. [7] Hadjinicolaou AV, Nisar MK, Parfrey H, et al. Non-infectious pulmonary toxicity of rituximab:a systematic review[J]. Rheumatology(Oxford),2012,51(4):653-662. [8] Fernández Casares M, Espósito G, González A, et al. Rituximab-induced interstitial lung disease[J]. Medicina (B Aires),2013,73(4):343-345. [9] Wagner SA, Mehta AC, Laber DA. Rituximab-induced interstitial lung disease[J]. Am J Hematol,2007,82(10):916-919. [10] Subramanian M, Manjunath R, Kilara N, et al. Rituximab-induced subacute interstitial pneumonitis:a case report and review of literature[J]. J Cancer Res Ther, 2010, 6(3):344-346. [11] Katsuya H, Suzumiya J, Sasaki H, et al. Addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy has a high risk of developing interstitial pneumonia in patients with non-Hodgkin lymphoma[J]. Leuk Lymphoma,2009,50(11):1818-1823. [12] Kong H,Wang Y,Zeng X,et al. Involvement of NLRP3 inflammasome in rituximab-induced interstitial lung disease:a case report[J]. J Clin Pharm Ther,2014,39(6):691-694. [13] Kubo K,Azuma A,Kanazawa M,et al. Consensus statement for the diagnosis and treatment of drug-induced lung injuries[J]. Respir Investig,2013,51(4):260-277. [14] Leon RJ, Gonsalvo A, Salas R, et al. Rituxmab-induced acute pulmonary fibrosis[J]. Mayo Clin Proc,2004,79(7):949,953. [15] Bitzan M, Anselmo M, Carpineta L. Rituxmab(B-cell depleting antibody) associated lung injury(RALI):a pediatric case and systematic review of the literature[J]. Pediatr Pulmonol,2009,44(9):922-934. |